RxDoctor Payments Data

Jose Rivera, PA

Physician Assistant · Cudahy, CANPI 1003937194

Payments from drug & device makers

$8,942in general payments, 2019–2025

Across 418 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$877
  • Boehringer Ingelheim$866
  • Lilly USA, LLC$814
  • Novo Nordisk$706
  • AstraZeneca$623
  • GSK$423
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$2313%
  • Food & beverage$8,52695%
  • Education$1852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,942 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$28,158
Medicare patients
120
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin166$175,153
TrulicityDulaglutide80$96,862
FarxigaDapagliflozin Propanediol73$71,046
EliquisApixaban67$56,831
JanuviaSitagliptin Phosphate39$36,207
Bydureon BciseExenatide Microspheres16$30,545
TradjentaLinagliptin33$29,669
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,982
OzempicSemaglutide21$21,226
XareltoRivaroxaban20$18,539
EntrestoSacubitril/Valsartan12$18,460
SynjardyEmpagliflozin/Metformin Hcl12$15,402
CreonLipase/Protease/Amylase15$14,143
JanumetSitagliptin Phos/Metformin Hcl13$10,568
MyrbetriqMirabegron11$7,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$866$220,224211 claims
Lilly USA, LLCTrulicity$814$96,86280 claims
AstraZenecaFarxiga$623$71,04673 claims
PfizerEliquis$333$56,83167 claims
MerckJanuvia, Janumet$314$46,77552 claims
GSKTrelegy Ellipta, Shingrix$423$25,90041 claims
Novo NordiskOzempic$706$21,22621 claims
Johnson & JohnsonXarelto$877$18,53920 claims
NovartisEntresto$356$18,46012 claims
AbbVieCreon$128$14,14315 claims
Astellas Pharma US IncMyrbetriq$304$7,03311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Cudahy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →